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Kwak, Young L., Keith A. Jones, David O. Warner, and
William J. Perkins. NO responsiveness in pulmonary artery and
airway smooth muscle: the role of cGMP regulation. Am J Physiol
Lung Cell Mol Physiol 290: L200–L208, 2006. First published Au-
gust 19, 2005; doi:10.1152/ajplung.00186.2005.—The purpose of this
study was to assess intrinsic smooth muscle mechanisms contributing
to greater nitric oxide (NO) responsiveness in pulmonary vascular vs.
airway smooth muscle. Canine pulmonary artery smooth muscle
(PASM) and tracheal smooth muscle (TSM) strips were used to
perform concentration response studies to an NO donor, (Z)-1-[N-(2-
aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate
(DETA-NO). PASM exhibited a greater NO responsiveness whether
PASM and TSM were contracted with receptor agonists, phenyleph-
rine and acetylcholine, respectively, or with KCl. The 10-fold
difference in NO sensitivity in PASM was observed with both sub-
maximal and maximal contractions. This difference in NO respon-
siveness was not due to differences in endothelial or epithelial
barriers, since these were removed, nor was it due to the presence of
cGMP-independent NO-mediated relaxation in either tissue. At
equal concentrations of NO, the intracellular cGMP concentration
([cGMP]i) was also greater in PASM than in TSM. Phosphodiesterase
(PDE) inhibition using isobutylmethylxanthine indicated that the
greater [cGMP]i in PASM was not due to greater PDE activity in
TSM. Expression of soluble guanylate cyclase (sGC) subunit mRNA
(2  0.2 and 1.3  0.2 attomol/g total RNA, respectively) and
protein (47.4  2 and 27.8  3.9 ng/mg soluble homogenate protein,
respectively) was greater in PASM than in TSM. sGC1 and sGC1
mRNA expression was equal in PASM but was significantly different
in TSM, suggesting independent regulation of their expression. An
intrinsic smooth muscle mechanism accounting for greater NO re-
sponsiveness in PASM vs. TSM is greater sGC activity.
nitric oxide; soluble guanylate cyclase; guanosine 3,5-cyclic mono-
phosphate; phosphodiesterase; pulmonary artery; airway smooth mus-
cle; molecular sequence data
AIRWAY SMOOTH MUSCLE APPEARS to be less responsive to exog-
enously administered nitric oxide (NO) and NO donors than
the pulmonary arterial circulation (6). For example, concentra-
tions of inhaled NO that reduce pulmonary vascular resistance
have only a slight beneficial effect in cases of symptomatic
airway constriction (19, 21). Similarly, intravenous adminis-
tration of NO donors temporarily reduces systemic and pulmo-
nary arterial vascular resistance but has not been notably
effective in the treatment of airway constriction (24). There are
a variety of reasons that could contribute to differences in NO
responsiveness in smooth muscle in the pulmonary vasculature
and airways, including differences in the barriers separating the
underlying smooth muscle from exogenously administered NO
(27) and differences in the NO response system in smooth
muscle from the two tissues. The present studies focus on
intrinsic smooth muscle contributions from these two tissues to
differences in NO responsiveness.
The primary initial enzyme in the smooth muscle NO re-
sponse system is soluble guanylate cyclase (sGC) (18, 33).
Active sGC usually exists as a heterodimer of two subunits,
primarily sGC1 and sGC1, in vascular smooth muscle,
although other subunits are known to exist, including sGC2,
sGC2i, and sGC2. These subunits can form other active
heterodimers (14, 49), some of which have lower NO inducible
activity. sGC activity is significantly increased by NO binding
at the sGC subunit heme (46) to catalyze the conversion of
guanosine 5-triphosphate to guanosine 3,5-cyclic mono-
phosphate (cGMP). Homodimers of sGC (e.g., sGC1/sGC1)
can form but have no activity (48), indicating that while only
one subunit is involved in NO binding, both subunits are
required in the dimer for enzyme activity (5). The finding that
sGC homodimers form in expression systems raises the possi-
bility that they may also exist in tissues expressing this en-
zyme. Intracellular cGMP concentration ([cGMP]i) is also
regulated by calmodulin-dependent and -independent phos-
phodiesterases (PDE), with roughly equal contributions from
both classes of PDE in pulmonary artery (29, 38). [cGMP]i
plays a variety of roles in the smooth muscle cell, most of them
mediated by cGMP-dependent protein kinases (cGK) with the
salient cGMP/cGK-mediated mechanism for smooth muscle
relaxation related to reductions in myoplasmic Ca2 (13) and
sensitivity of the myofilament contractile proteins to Ca2 (37,
40, 42). Differences in the NO response system in smooth
muscle may thus exist at the level of cGMP production (i.e.,
sGC activity), PDE-mediated cGMP breakdown, and cGMP
responsiveness. Smooth muscle in both the pulmonary vascu-
lature and airways contains the enzymes necessary to transduce
NO signaling, including sGC (4, 6, 11, 43) and cGK (1, 9, 10,
12, 36, 47), although the level of sGC and cGK expression in
these tissues has not been quantified.
In the present study, we determined the effects of NO on
tissue [cGMP]i and relaxation following a standardized con-
traction in pulmonary artery and airway smooth muscle [pul-
monary artery smooth muscle and tracheal smooth muscle
(PASM and TSM, respectively)]. We tested the hypothesis that
the NO responsiveness of PASM is greater than that of TSM in
part because of greater protein expression of sGC in the former
tissue, consequently producing higher tissue cGMP at a given
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NO concentration. In the course of these studies, the types and
levels of sGC subunit expression were semiquantitatively de-
termined in these tissues for the first time.
MATERIALS AND METHODS
Tissue preparation. After Institutional Animal Care and Use Com-
mittee approval, mongrel dogs of either sex were anesthetized with an
intravenous injection of pentobarbital sodium (30 mg/kg) and exsan-
guinated by bilateral transection of the carotid arteries. The trachea
and lungs were excised and immersed in chilled physiological salt
solution (PSS) of the following composition (in mM): 110 NaCl, 26
NaHCO3, 5.6 dextrose, 3.4 KCl, 2.4 CaCl2, 1.2 KH2PO4, and 0.8
MgSO4. Third-generation pulmonary artery was dissected from the
lung parenchyma, cut into rings, and cleaned of adventitia under
microscopic observation, and the endothelium was removed by gentle
rubbing of the luminal surface with a moist cotton swab. The fat,
connective tissue and the epithelium were removed with tissue forceps
and scissors under microscopic observation to make muscle strips.
The NO responsiveness of first- to fourth-generation pulmonary
artery was not significantly different (unpublished observations), and
third-generation pulmonary artery was used in these studies due to
ease of preparation and definition of myocyte orientation. Higher-
generation airways were not used due to difficulties in separating
epithelial cells from smooth muscle cells, which was undesirable in
the biochemical and expression studies.
Mechanical measurements. TSM and PASM strips were mounted
in 5-ml water-jacketed tissue baths that were filled with PSS (37°C)
aerated with O2/CO2, 94%:6%, pH 7.4. One end of the strips was
anchored to metal hooks at the bottom of the tissue bath; the other end
was attached to a calibrated force transducer (model FT03D; Grass
Instruments/Astro-Med, West Warwick, RI). During a 3-h equilibra-
tion period, the strips were repeatedly contracted isometrically with 40
mM KCl and then relaxed. The length of the strips was increased after
each contraction-relaxation cycle until active force was maximal
(optimal length). Relaxed PA strips were then contracted with nor-
epinephrine (1 M), and the absence of endothelium was verified by
failure of acetylcholine (1 M) to cause relaxation. Strips were then
relaxed again until commencement of a study. Before concentration-
response studies, all strips were incubated with 10 M indomethacin
to prevent the formation of prostanoids. In previous studies, contrac-
tion of TSM and PASM during incubation with indomethacin had no
effect on tissue [cGMP]i (20).
Concentration-response curves. Concentration responses to the NO
donor in TSM and PASM were obtained 15 min following an
isometric contraction using either a physiological contractile agonist
or KCl. The contractile agonists used were acetylcholine and phen-
ylephrine for TSM and PASM, respectively. The NO donor (Z)-1-[N-
(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate
(DETA-NO) was selected since it slowly releases NO (23), giving rise
to stable relaxations at a given [DETA-NO], and does not require
biotransformation to release NO (30). DETA-NO concentration re-
sponse studies were performed with contractile agonists and KCl to
test for the possibility that any difference in DETA-NO response
could be attributed to differences in contractile mechanism between
TSM and PASM. DETA-NO concentration response curves were
performed under conditions of both maximal and submaximal con-
traction for both contractile agonists and KCl. We determined sub-
maximal concentrations of both contractile agonist and KCl by ini-
tially contracting the strip to maximal isometric force, allowing it to
fully relax after washout and adding contractile agent until the
isometric force attained 50  10% of the maximal value. In the initial
experiment, the effects of 10 M sGC inhibitor 1H-[1,2,4]Oxadia-
zole[4,3-a]quinoxalin-1-one (ODQ) and 100 M -phenyl-1,N2-
etheno-8-bromoguanosine-3,5-cyclic monophosphorothioate, Rp-
isomer, a membrane-permeant, phosphodiesterase-resistant cGMP-
dependent protein kinase inhibitor (cGKi), on DETA-NO-induced
relaxation was examined to assess the presence of cGMP- or cGK-
independent relaxation. Studies were done at both maximal and
submaximal isometric force to determine whether the DETA-NO
concentration response was sensitive to the degree of smooth muscle
activation. In all concentration-response curves, the relaxation is
indexed to the isometric force obtained just before the addition of
DETA-NO (control condition) and is expressed as a percentage of
control.
Cyclic nucleotide measurements. TSM and PASM strips were
incubated in 10-ml baths and aerated with PSS at 37°C. Strips were
treated with a stated concentration of DETA-NO in the presence or
absence of 500 M isobutylmethylxanthine (IBMX) and were then
snap frozen with liquid nitrogen and stored in a 70°C freezer. Strips
were then homogenized, and the soluble extract was assayed for
cGMP with a commercially available RIA kit (Amersham Bio-
sciences) as previously described (39). The protein concentration in
the tissue homogenate was determined by the method described by
Lowry et al. (28), using bovine serum albumin dissolved in 1 N NaOH
as the standard. Tissue [cGMP]i was expressed in pmol/mg protein.
Strips treated with IBMX were incubated with this agent for 10 min
before the addition of DETA-NO. Two sets of experiments were
performed. The first examined the time course of increases in [cGMP]i
following addition of DETA-NO to both tissues. The second used this
information to select the sample time for examining the effects of
DETA-NO, IBMX, and IBMX  DETA-NO on [cGMP]i accumula-
tion in both tissues.
sGC subunit sequencing. Total RNA was prepared from RNAlater
(Ambion, Austin, TX)-treated TSM and PASM tissue by extraction
with guanidinium isothiocyanate and subsequent sedimentation
through CsCl (8). RNA quality was assessed by RNA electrophoresis
on an agarose gel. Only samples in which the ratio of 28S/18S
ribosomal RNA bands was at least 1.2 and with little evidence of
laddering below or between these bands were studied. mRNA was
isolated from total RNA using Micro-Fast Track (Invitrogen, Carls-
bad, CA) and was then reverse transcribed using avian myeloblastosis
virus reverse transcriptase (Clontech, Mountain View, CA). The
resulting single-stranded cDNA was probed by rapid amplification of
cDNA ends (Clontech), using adapter sequences and a sequence for
the sGC subunit that was highly conserved across species. For sGC1,
nucleotides 2198–2200 of the rat sequence (34) (accession no.
M36075) and, for sGC1, nucleotides 1701–1679 of the human
sequence (17) (antisense, accession no. X66533) were used as the
initial probes for touchdown PCR. The resulting cDNA band was
purified from an agarose gel and subcloned into pCR2.1 vector using
TOPO TA cloning kit (InVitrogen). Positive Escherichia coli colonies
were tested for the insert with colony PCR using M13 forward and
reverse primers. Plasmid containing the insert was purified from a
broth culture of a positive colony using Wizard plasmid miniprep
(Promega, Madison, WI). The sequence of the insert was initially
characterized with M13 forward and M13 reverse primers by the
Sanger dideoxy method (41) at the Mayo Rochester DNA Sequencing
and Synthesis Core Facility (Rochester, MN). These sequences were
used to generate new primers to extend the sequence until the
complete open frame was obtained. Overlapping sequences were used
to design gene-specific sequencing primers for obtaining the full-
length open reading frame sequence of each sGC subunit in triplicate.
The resulting canine sGC1 and sGC1 sequences were submitted to
the National Center for Biotechnology Information and have acces-
sion numbers DQ008575 and DQ008576, respectively. Oligonucleo-
tide probes and primers were synthesized at the Mayo Rochester Core
Facility. Oligonucleotide primers designed on the basis of published
sequences were used to probe for sGC2, sGC2i, and sGC2 subunit
isoforms (accession nos. X63282, Z50053, and M57507, respec-
tively).
Measurement of sGC mRNA expression. cDNA was prepared from
total RNA from tissues taken from separate animals and stored at
20°C until the time for determination of sGC subunit cDNA
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concentration. Quantitative RT-PCR was used for this determination
(2, 16). The exogenous internal standards (mimes) were derived from
pBR322 and composite primers for PCR amplifying these were
produced as described in Table 1. The pBR322 sequence was selected
to have a melting point by nearest neighbor estimation (Oligo Soft-
ware, Cascade, CO) within 2°C of the sGC subunit sequence being
amplified. The respective size of the mime-sGC amplicon sequences
were 345:225 and 348:398 bp for sGC1 and sGC1, respectively.
The amplified mime sequences were purified and subcloned into
pCR2.1 plasmid using TOPO TA cloning (Invitrogen), and colonies
containing the mime insert were selected as described above in sGC
subunit sequencing. Plasmid was purified from the E. coli pellet using
a QIAfilter Plasmid Maxi Kit (Qiagen, Valencia, CA). Confirmation
of insertion was obtained by sequencing the plasmid and testing for
amplification with sGC subunit-selective primers. Plasmid and mime
concentrations were quantitated using optical density at 260 nm.
Mime cDNA concentrations for determination of sGC cDNA concen-
tration in total RNA from TSM and PASM were 0.01, 0.025, 0.05,
0.1, 0.25, and 0.5 amol for both sGC subunits. Samples underwent
PCR for 30 cycles with the following cycling conditions: 30 s initial
denaturation at 94°C, followed by 25 cycles of 10 s denaturation at
94°C, and 2 min 30 s annealing and extension at 68°C with a final
extension at 72°C for 3 min. The PCR products were run on a 2.5%
composite agarose gel [1.5% LMP Ultrapure agarose  1% Ultrapure
agarose (Invitrogen)] containing 500 ng/ml ethidium bromide for
staining. Gels were digitized using an AlphaInnotech ChemImager400
imaging system, and the resulting images were analyzed with Opti-
quant software (PerkinElmer, Boston, MA). The amount of gene-
specific mRNA was determined by linear regression analysis of a plot
of log [intensity mime/intensity sample] vs. log [moles mime in PCR
reaction]. The point at which the regression line crosses 0 on the
y-axis determines the number of moles of sGC subunit mRNA present
in the original total RNA sample. The quantity of gene-specific
mRNA is expressed in amol/g total RNA.
Measurement of sGC protein expression. TSM and PASM strips,
10–20 mg wet weight, were flash frozen by rapid immersion in a dry
ice-acetone slurry. The tissue strips were then placed in homogenizing
tubes and homogenized in the presence of 100 l of extraction buffer
(in mM, 10 Tris HCl, 150 NaCl, 10 dithiothreitol, 1 Na2EDTA, 1
phenylmethylsulfonyl fluoride, 1 benzamidine, and 10 g/ml leupep-
tin, aprotinin, pepstatin Am, and antipain, pH 7.4). The tubes were
then centrifuged at 4,000 g for 10 min to pellet solids. Protein
concentration in the supernatant was determined by the Lowry
method. Approximately 20 g of protein in Laemmli buffer (Bio-Rad)
were loaded per lane. Known amounts of purified sGC protein (Alexis
Biochemicals, Lausen, Switzerland) were loaded in adjacent lanes to
generate a standard curve. Proteins were separated by electrophoresis
in SDS-7.5% polyacrylamide precast minigels (Bio-Rad) with Tris-
Glycine-SDS buffer. The proteins were transferred to a polyvinyli-
dene difluoride membrane in Tris-Glycine buffer for 45 min at 100 V,
and the membrane was washed with 10 mM Tris-buffered saline
containing 5% (wt/vol) bovine serum albumin for 15 min (25°C). The
membrane was then treated with Tris-buffered saline containing 0.2%
Tween 20 and 1:10,000 dilution of sGC polyclonal rabbit antibody
(Cayman Chemical, Ann Arbor, MI) overnight. After being washed,
the membrane was treated with 1:10,000 anti-rabbit horseradish per-
oxidase-conjugated IgG antibody (Santa Cruz Biotechnology, Santa
Cruz, CA) for 30 min and then washed again. Membranes were then
treated with enhanced chemiluminescence Western blotting reagents
(ECL; Amersham, Piscataway, NJ) for 1 min, apposed to Kodak
BioMax film, and developed for a period of time that avoided
saturation of any bands. The film was scanned and digitized with
Adobe Photoshop and subsequently analyzed with Optiquant software
(Packard Instruments).
Materials. DETA-NO, ODQ, and -phenyl-1,N2-etheno-8-bromo-
guanosine-3,5-cyclic monophosphorothioate, Rp-isomer, a mem-
brane-permeant, phosphodiesterase-resistant cGKi were purchased
from Alexis Biochemicals. Unless otherwise specified, all other chem-
icals were purchased from Sigma-Aldrich (St. Louis, MO). With the
exception of ODQ and cGKi, which were dissolved in 50% DMSO,
all drugs and chemicals were dissolved in distilled water.
Analysis of data. Data are expressed as means  SE; n represents
the number of dogs. The effects of DETA-NO on isometric force and
[cGMP]i were assessed by repeated-measures ANOVA with post hoc
analysis by Duncan’s multiple-range test. Concentration-response
curves were compared by nonlinear regression analysis as described
by Meddings et al. (31). In this method, force (F) at any concentration
of drug (C) is given by the equation F 	 FmC/(EC50  C), where Fm
represents the maximal isometric force and EC50 represents the
concentration that produces half-maximal isometric force for that
drug. Nonlinear regression analysis was used to fit values of Fm and
EC50 to data for F and C for each condition studied. This method
allows comparison of curves to determine whether they are signifi-
cantly different and whether this overall difference can be attributed to
differences in Fm, EC50, or both parameters. A P value 
0.05 was
considered statistically significant.
RESULTS
Physiological studies. In both PASM and TSM, following an
initial submaximal contraction with 25 mM KCl and 15-min
treatment with the specified inhibitors, the relaxation to
DETA-NO was stable (data not shown) at each concentration
and was complete at the highest concentration. DETA-NO-
induced relaxation was significantly decreased by 10 M
ODQ, an sGC inhibitor, and 30 M cGKi and was completely
inhibited by the combination of the sGC and cGKi, except at
the 104 DETA-NO concentration in PASM (Fig. 1). The
addition of ODQ, cGKi, and DMSO alone (
0.2%) had no
effect on KCl-induced contractions in PASM or TSM (data not
shown).
Phenylephrine (10 M) and acetylcholine (1 M) produced
maximal isometric force in PASM and TSM, respectively (data
Table 1. Composite primer sequences
Subunit Sequence
Nucleotide No.
sGC pBR322
sGC1
Sense GGTTGTGCAAGCCAAGAAGTTCAGGATCGTTGTCAGAAGTAAGTTGG 1770–1794 3734–3756
Antisense GGGTGTCACTTTCTTTGTGCAATCCGGGTTACATCGAACTGGATCTC 1994–1970 4028–4007
sGC1
Sense GATACAATCTTGCGTGTCCTGGGATCGATCGTTGTCAGAAGTAAGTTGG 271–296 3734–3756
Antisense GCTTTGCAGAAGGTATATGGGCTGATGGGGTTACATCGAACTGGATCTC 668–642 4028–4007
Composite primer sequences showing sequences used to probe for soluble guanylate cyclase (sGC) subunit cDNA and mime constructed from sGC subunit
sequence  specified (bold) pBR322 sequence.
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not shown). In the presence of agonists sufficient to achieve
50% maximal isometric force (0.2 M phenylephrine and
0.1 M acetylcholine), DETA-NO produced complete relax-
ation (Fig. 2, left). The log EC50 for DETA-NO was signifi-
cantly less for PASM compared with TSM (6.49  0.13 and
5.24  0.12 M, respectively; P 
 0.001). A similar pattern
of results was observed during maximal contractions with
agonists (log EC50 for DETA-NO in PASM and TSM of
6.09  0.08 and 4.7  0.08 M, respectively; P 
 0.001)
(Fig. 2, right). DETA-NO produced complete relaxation of
maximally contracted PASM and TSM.
Maximal isometric force in response to KCl in PASM and
TSM was achieved with 40 and 60 mM KCl, respectively (data
not shown). During KCl activation achieving 50% maximal
isometric force (requiring 25 and 21 mM for PASM and TSM,
respectively) DETA-NO produced complete relaxation of both
tissues (Fig. 3, left). The log EC50 for DETA-NO was less in
PASM and TSM (5.73  0.11 and 4.99  0.96 M,
respectively; P 
 0.001). A similar pattern of results was
observed during maximal contractions produced by KCl (log
EC50 of 5.34 0.13 and 4.44 0.07, respectively; P
 0.001,
Fig. 3, right). Relaxation to DETA-NO was incomplete during
maximal KCl activation.
Tissue cGMP ([cGMP]i) was slightly, but significantly,
greater in PASM compared with TSM in the absence of
DETA-NO (0.48  0.04 and 0.30  0.03 pmol/mg protein,
respectively; P 	 0.008, Fig. 4). No increase in [cGMP]i could
be detected atEC50 (PASM and TSM) or EC90 (TSM). At 10
times EC90 DETA-NO [cGMP]i increased in both tissues
within 30 s (P 
 0.001). The [cGMP]i did not significantly
change at 60 s or 15 min (Fig. 4).
DETA-NO at 10 M (EC90 in PASM and EC50 in TSM)
produced an increase in [cGMP]i in PASM, but not in TSM
(0.99  0.10 and 0.36  0.07 pmol/mg protein, P 
 0.001).
DETA-NO at 100 M produced an increase in [cGMP]i in
PASM and TSM (4.85  0.69 and 1.44  0.24 pmol/mg
protein, respectively), and this increase was significantly
greater in PASM (P 	 0.009). Exposure to the general PDE
inhibitor IBMX for 10 min slightly, but significantly, increased
basal [cGMP]i in PASM, but not TSM. IBMX augmented the
increases in [cGMP]i produced by 10 M and 100 M
DETA-NO in both tissues (Fig. 5). This augmentation was
Fig. 1. Effects of the nitric oxide (NO) donor
(Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)-
amino]diazen-1-ium-1,2-diolate (DETA-NO)
on isometric force in pulmonary artery smooth
muscle (PASM, left) and tracheal smooth mus-
cle (TSM, right). Strips were contracted to half-
maximal isometric force with KCl. DETA-NO con-
centration response curves were obtained without
(Control) and with 10M soluble guanylate cyclase
inhibitor1H-[1,2,4]Oxadiazole[4,3-a]quinoxalin-1-
one (ODQ), 100 M -phenyl-1,N2-etheno-8-
bromoguanosine-3,5-cyclic monophos-
phorothioate, Rp-isomer, a cGMP-dependent
protein kinase inhibitor (cGKi), and both inhib-
itors (ODQ  cGKi). Data are presented as
means  SE; n 	 6.
Fig. 2. Effects of the NO donor DETA-NO on
isometric force in PASM and TSM strips con-
tracted to half-maximal (left) and maximal
(right) isometric force with phenylephrine in
the case of PASM and acetylcholine in the case
of TSM. Data are presented as means  SE;
n 	 6.
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greater for PASM than for TSM at both DETA-NO concen-
trations.
Expression studies. The mRNA sequence was determined
for the sGC subunit sequences most abundantly expressed in
these smooth muscle tissues. A very small amount of sGC2
was found exclusively associated with PASM (
1% the
amount of other subunits), but this was taken to be due to
contamination from residual adventitia and was not further
pursued. sGC2, sGC2i, and sGC2 mRNA expression was
not detected in either tissue. Both sGC1 and sGC1 were
expressed at significant levels in both tissues and were se-
quenced through the complete open reading frame. In the open
reading frame, sGC1 was 88% homologous to the human and
90% homologous to rat and bovine sGC1 sequences (ac-
cession nos. Y17523, M36075, and X54014, respectively).
This sequence is identical to that predicted from genomic
sequences for Canis familiaris (accession no. XM539780) with
the exception of a 150-bp insert in the predicted sequence
between nucleotides 2077 and 2078 in the sequence obtained in
these studies. This insert would result in insertion of 50 amino
acids between amino acids 572 and 573 of the inferred amino
acid sequence. Such an insert is not present in sGC1 mRNA
sequences reported for other species. It is thus likely that the
insert present in the genomically predicted sequence for sGC1
in C. familiaris is intron sequence. The inferred sGC1 amino
acid homology and identity were 95 and 90% for the human,
rat, and bovine sequences.
The sGC1 mRNA sequence was 95% homologous with
the human, rat, and bovine nucleotide sequences (accession
Fig. 3. Effects of the NO donor DETA-NO on
isometric force in PASM and TSM contracted
to half-maximal (left) and maximal (right) iso-
metric force with KCl. Data are presented as
means  SE; n 	 6.
Fig. 4. Changes in intracellular cGMP concentration ([cGMP]i) as a function
of time following treatment of PASM (black) and TSM (white) with 100 and
500 M NO donor DETA-NO, respectively. Data are presented as means 
SE, n 	 8.
Fig. 5. Effects of isobutylmethylxanthine (IBMX, 500 M) on intracellular
cGMP ([cGMP]i) measured 10 min after addition of the NO donor DETA-NO
at the specified concentration to PASM and TSM. *Increase in [cGMP]i was
greater in PASM vs. TSM at the specified condition, P 
 0.05. #[cGMP]i
differs significantly from the value obtained in the absence of IBMX, P
 0.05.
Data are presented as means  SE, n 	 8.
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nos. X66533, M22562, and Y00770, respectively). The in-
ferred amino acid homology and identity for this sGC subunit
were 99 and 98% compared with the human, rat, and bovine
inferred amino acid sequences. The predicted molecular
weights of canine sGC1 and sGC1 were 77,500 and 70,500,
respectively.
The data set used to determine the mRNA expression for
sGC1 subunit is shown in Fig. 6, left. In this example, the plot
of Log (mime/sample) vs. Log (mime) indicates that there is
more sGC1 in PASM than in TSM. The level of expression of
both sGC1 and sGC1 was greater (P 
 0.025) in PASM,
2.0  0.23 and 1.7  0.2 amol/g total RNA, respectively,
than in TSM, 0.6  0.2 and 1.3  0.2, respectively (Fig. 6,
right). The level of sGC1 mRNA expression was significantly
lower than that of sGC1 in TSM (P 
 0.05), but expression
of the two sGC subunits was equal in PASM.
An example of a purified sGC protein at six concentrations
with equal loading of tissue homogenates from PASM and
TSM on the same gel is shown in Fig. 7, left. A best-fit line was
obtained with a sigmoidal curve, and the equation of this line
was used to calculate the sGC protein concentration in the
tissue homogenates. sGC protein expression was greater (P 

0.001) in PASM than in TSM, 47.4  2 and 27.8  3.9 ng/mg
soluble homogenate protein (Fig. 7, right).
DISCUSSION
Relaxation to the NO donor DETA-NO occurs via the
NO-cGMP signaling system in both PASM and TSM at all but
the highest concentration of DETA-NO used in the pulmonary
artery. The significant, but small, reduction in isometric force
that occurred at 104 M DETA-NO in PASM either reflects the
fact that the concentrations of the sGC and cGKi used do not
completely overcome the effects of NO-mediated sGC activa-
tion at very high NO concentrations or that cGMP-independent
relaxation becomes evident only at high NO concentrations.
The observation that the combination of the sGC and cGKi
prevented DETA-NO-induced relaxation to a greater extent
than either agent alone suggests that the former explanation is
more likely. The possibility that the difference in NO respon-
siveness between PASM and TSM is due to the presence of a
significant cGMP-independent mechanism in one of them is
thus unlikely. Although cGMP-independent relaxation to NO
donors in TSM has been previously reported (39, 50), this was
observed with a different class of NO donors, nitrosothiols and
sodium nitroprusside. The present results corroborate those
obtained using an NO donor and the sGC inhibitor ODQ in
aortic rings and platelets (32). The finding that NO-mediated
relaxations in both tissues are cGK dependent differs from
Fig. 6. Soluble guanylate cyclase (sGC) subunit mRNA expression in PASM and TSM by quantitative RT-PCR. Left: data illustrating the method for determining
the amount of sGC1 found in PASM and TSM. The dashed line indicates the point in the curves at which mime is equal to the sample, and this value is
determined for each sample by interpolation. Inset: an example of an ethidium bromide agarose gel with mime cDNA bands above sample bands. Right: the
amount of each sGC subunit mRNA present in PASM and TSM. *The amount of both sGC subunits is greater in PASM (P 
 0.025). #The amount of sGC1
in TSM is greater than the amount of sGC1 mRNA (P 
 0.05). Data are presented as means  SE, n 	 6.
Fig. 7. The amount of sGC protein in the
soluble fraction of tissue homogenates from
PASM and TSM by a semiquantitative im-
munoblotting method. Left: representative
data using known amounts of purified bovine
lung sGC to create a standard curve (sGC
Std) and 20 g of homogenate from each
tissue. Inset: representative experiment of an
immunoblot used to generate the standard
curve and tissue data points. Right: semiquan-
titative measurement of the amount of sGC in
PASM and TSM. *The amount of sGC in
PASM is greater than in TSM, P 
 0.001.
Data are presented as means  SE, n 	 6.
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findings of a cGMP-dependent, cGK-independent NO donor-
mediated relaxation in cat TSM (45), but this may be due to the
use of a nitrosothiol NO donor or a species difference in the
TSM preparation. Possible differences in bioconversion or
permeability of the NO donor in PASM and TSM playing a
role in NO responsiveness are also unlikely since DETA-NO
does not require or undergo appreciable bioconversion to
release NO (22, 23), which is highly membrane permeant.
TSM was less responsive to NO than PASM by more than an
order of magnitude, under conditions that carefully matched
the degree of agonist-induced contraction. Similar differences
were observed regardless of the level of activation. The recep-
tor-activated mechanisms used for the two different smooth
muscle preparations were different, raising the possibility that
the difference in NO responsiveness was due to differences in
the receptor signaling giving rise to the initial contraction,
although both agonists ultimately converge on a common
pathway in which myoplasmic Ca2 and Ca2 sensitivity are
increased (42). This is a possibly relevant consideration, since
the mechanism by which cGMP and cGMP-dependent protein
kinase decreases contraction in smooth muscle has not been
clearly established. However, a similar pattern of results was
found when membrane depolarization with KCl was used to
induce contraction, suggesting that the observed difference
between the two tissues does not depend upon the mechanism
of contraction. Because KCl results in smooth muscle contrac-
tion predominantly by increasing calcium influx and [Ca2]i,
these results suggest that the difference in NO responsiveness
between the two tissues is not due to differences in regulation
of Ca2 sensitivity, although more direct evidence would be
required to demonstrate this. These results corroborate and
extend previous results demonstrating a greater NO respon-
siveness in bovine pulmonary artery compared with TSM (6).
The EC50 concentration of DETA-NO in both tissues seems
relatively high, between 106 and 105 M, but can be ex-
plained by the slow NO release kinetics, with a half-life of24
h at 37°C. An estimate of the NO concentration in the tissue
bath, assuming apparent first-order kinetics for NO release and
2 NO released/DETA-NO, indicates that at 3 min, 106–105
M DETA-NO results in 2.8–28 nM NO. Even this estimate is
probably high, due to the fact that the bath system is open and
bubbled with oxygen, which reacts with NO. The NO concen-
tration resulting in 50% relaxation in PASM and TSM in the
present study is thus likely lower than previously reported
values using NO gas as the source (6, 43) and is in closer
agreement with the potency of NO in inducing relaxation in
vascular smooth muscle using flash photolysis on a membrane-
permeant, photolabile NO-releasing compound (3, 7).
Addition of EC50 concentrations of the NO donor to the
two tissues resulted in no detectable increase in [cGMP]i,
indicating that much of the relaxation to NO occurs with
increases in cGMP that cannot be measured under steady-state
conditions (i.e., in the absence of PDE inhibitors). Thus higher
DETA-NO concentrations were used to determine the kinetics
of [cGMP]i in the absence of PDE inhibitors. A rapid increase
in [cGMP]i that did not significantly change after 30 s was
observed in both tissues. This indicates that a steady-state
condition in which cGMP production by sGC and breakdown
by PDE is obtained rapidly in both tissues even at this rela-
tively high NO donor concentration and is compatible with the
stable relaxations obtained in both tissues with DETA-NO. It is
interesting that nearly equipotent DETA-NO relaxant concen-
trations also had a similarly equipotent effect on [cGMP]i. This
suggests that the relationship between [cGMP]i and relaxation
using this NO donor is similar between PASM and TSM,
although this study does not systematically explore this rela-
tionship in either tissue.
Measurement of [cGMP]i in the presence and absence of the
general PDE inhibitor IBMX demonstrated significant cGMP
regulation in both tissues by PDE. IBMX, rather than a type V
PDE-specific inhibitor, was selected since regulation of cGMP
by PDE in PASM is not necessarily either type V selective or
even predominant (29, 38). Although PDE types in airway
smooth muscle have been explored (15, 44) the role of PDE
types on cGMP conversion to GMP in TSM has not been
determined. Thus the findings that the ratio of [cGMP]i ob-
tained in the presence of DETA-NO with and without IBMX
and the absolute increase in [cGMP]i with and without
DETA-NO was greater in PASM than in TSM suggest that the
lower [cGMP]i in TSM vs. PASM at a given NO donor
concentration is not due to greater PDE-mediated cGMP break-
down in TSM. The results, in fact, suggest that PDE activity
results in greater cGMP breakdown in PASM than in TSM, but
a direct measurement of cGMP PDE activity in both tissues
would be required to unambiguously demonstrate this.
The greater NO responsiveness of PASM vs. TSM is related
in part to a greater increase in [cGMP]i induced by a given NO
concentration. Because NO-induced cGMP production occurs
exclusively via sGC, the results of these studies indicate that
PASM must have greater sGC activity than TSM. Differences
in sGC activity may be due to either increased expression of
active sGC enzyme or increased sGC activity per unit of the
enzyme present in the tissue (sGC-specific activity). Initial
probing of both PASM and TSM for expression of sGC subunit
mRNA indicated that only sGC1 and sGC1 are significantly
expressed in both tissues, the first time that this has been
systematically determined in either smooth muscle tissue. It is
therefore unlikely that specific activity regulation of sGC is due
to expression of different sGC subunits in PASM and TSM.
The levels of sGC subunit mRNA expression measured in
these studies are the first semiquantitative report of their
absolute, rather than relative, expression in smooth muscle
tissues. The quantitative RT-PCR method used in these studies
has the advantage of having an internal standard but may be
limited in accuracy by variability in the quality of the mRNA
in each preparation, the use of a cDNA rather than an RNA
mime, and differences in the PCR efficiency between the mime
insert sequence and the cDNA produced by reverse transcrip-
tion of mRNA in a total RNA sample. Variability in the quality
of RNA was assessed before the reverse transcription step, and
RNA samples showing evidence of noticeable degradation
were not reverse transcribed. The mime sequence in pBR322
was selected to have similar melting and annealing character-
istics to that of the sGC subunit sequence being probed. The
semiquantitative assessment of mRNA for each sGC subunit
demonstrated low variability across multiple total RNA prep-
arations and close agreement in the amount of mRNA mea-
sured for both sGC subunits in both tissues. Taken together
these precautions and findings suggest that random differences
in reverse transcription efficiency within and across tissues did
not contribute significantly to the measurement of sGC subunit
mRNA expression. The possibility of a systematic error due to
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use of a cDNA mime and reverse transcribed mRNA from
tissue total RNA samples still exists and cannot be addressed
with the methods used. Thus the values for sGC subunit
mRNA expression reported in these studies are best taken as a
precise lower limit.
The recent finding that homodimers of sGC subunits (e.g.,
sGC1/sGC1) can occur (48) suggests another mechanism by
which sGC expression might be regulated differently in two
tissues, despite expression of the same sGC subunits. Unequal
expression of the two sGC subunits would result in formation
of either a fraction of inactive (48) or less active (26) sGC
homodimer with the amount of active homodimer limited by
the less abundantly expressed sGC subunit. In the present
studies PASM expression of sGC1 and sGC1 subunits was
higher than in TSM and approximately equal, suggesting that
greater sGC activity in PASM is due, in part, to greater mRNA
expression of both sGC subunits. In TSM, sGC1 was less than
sGC1 subunit mRNA expression, suggesting the possibility of
sGC1 homodimer formation in this tissue. A similar obser-
vation of greater sGC1 mRNA expression has been previ-
ously reported in vascular smooth muscle (25), but verification
of this at the level of sGC subunit protein expression and direct
demonstration of sGC1 homodimer formation in a fully dif-
ferentiated smooth muscle tissue awaits further investigation.
In the absence of purified sGC subunit protein standards, it
was not possible to assess the specificity of commercially
available antibodies. sGC purified from bovine lung was used
as a protein standard, and a commercially available antibody
that was generated against antigenic peptides from both sGC1
and sGC1 was successfully used to detect sGC in canine
PASM and TSM. The method used in these studies to semi-
quantitatively determine sGC protein expression involved the
use of a protein standard, in this case purified bovine lung sGC
heterodimer to generate a standard curve. The amount of sGC
present in tissue homogenates was then determined using this
standard curve and interpolation, in a manner analogous to a
Bradford protein assay using a purified form of a protein as its
own standard. The amount of sGC used in the standard curve
was designed to ensure that the chemiluminescent signal from
sGC in tissue homogenates was in the midrange of the standard
curve. This is the first report of the amount of sGC protein
expressed in smooth muscle tissue. The amount sGC in the
soluble fraction of tissue homogenates reported here is signif-
icantly lower than that reported in rat brain (35), which may be
due to differences in tissue and/or species and the fact that sGC
concentration in the latter study was determined by only a
single sGC protein standard concentration, rather than a stan-
dard curve.
The commercially available sGC antibody used is described
as specific to sGC1, and the antigenic peptide sequence used
to generate this rabbit polyclonal antibody is identical across
all mammalian species, including dog. It is therefore improb-
able that use of the bovine lung sGC protein standard resulted
in a species-related difference in the anti-sGC antibody binding
to sGC in bovine vs. canine protein. A potential source of error
that cannot be accounted for with the methods used is that the
amount of sGC protein present in the commercially available
protein sample may be higher than described on the package
insert by as much as a factor of two. This would result in an
underestimation of the amount of sGC present in the canine
PASM and TSM tissue homogenates and would be a source of
error that would have an equal effect in both tissues. The
greater sGC protein found in PASM vs. TSM suggests that
most of the difference in sGC activity between the tissues is
accounted for by greater sGC expression, rather than greater
sGC-specific activity in PASM.
In summary, the present study demonstrates that relaxation
to NO in both PASM and TSM is attributable to both cGMP
and cGMP-dependent protein kinase mechanisms. This is true
for NO-mediated relaxation of submaximal and maximal con-
tractions induced by either receptor-agonists or membrane
depolarization. Thus mechanisms intrinsic to smooth muscle
contribute significantly to the clinical finding of apparently
greater NO responsiveness in pulmonary vasculature vs. air-
ways. The amount of cGMP under steady-state conditions was
greater in PASM than in TSM at a given NO concentration.
Differences in PDE activity plays little role in the greater NO
responsiveness of PASM. The only sGC subunits expressed in
significant amounts in PASM and TSM, sGC1 and sGC1,
were both more abundantly expressed in PASM than in TSM,
and this difference in expression appears to account for the
greater cGMP production in PASM. Another mechanism that
might contribute significantly to differences in the NO respon-
siveness between these tissues, differences in the responsive-
ness of the contractile system to the actions of cGMP, is not
addressed in these studies.
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